Literature DB >> 19616976

Hybrid endovascular and open treatment of severe multilevel lower extremity arterial disease.

G A Antoniou1, G S Sfyroeras, C Karathanos, H Achouhan, S Koutsias, G Vretzakis, A D Giannoukas.   

Abstract

OBJECTIVE: To evaluate the feasibility and efficacy of simultaneous combined endovascular and open lower extremity arterial reconstruction.
DESIGN: Case series study with retrospective analysis of prospectively collected non-randomised data.
METHODS: Patients were divided into three groups: group 1 and group 2 included patients who underwent endovascular reconstruction proximal and distal to the site of open reconstruction, respectively, whereas group 3 included patients who underwent open surgery with both proximal and distal endoluminal procedures. Patency analyses were performed using Kaplan-Meier life tables. Univariate and multivariate analyses were used to assess the influence of various risk factors on primary patency.
RESULTS: Complete data were obtained from 60 patients who underwent 61 single-step hybrid procedures. Technical and haemodynamic success rates were 100% and 95%, respectively. The perioperative mortality rate was 3%. The primary and assisted-primary patency rates at 12 months were 71% and 98%, respectively. Primary patency rates were lower in group 3 when compared with groups 1 and 2 (log-rank test, p=0.006). The presence of diabetes and dyslipidaemia were independent predictors of decreased primary patency (p=0.003 and p=0.014, respectively).
CONCLUSIONS: Hybrid procedures provide an effective treatment management of selected patients with multilevel lower extremity arterial disease. The extent of the disease, diabetes and dyslipidaemia are associated with worse outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19616976     DOI: 10.1016/j.ejvs.2009.06.016

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  7 in total

Review 1.  Bypass surgery for chronic lower limb ischaemia.

Authors:  George A Antoniou; George S Georgiadis; Stavros A Antoniou; Ragai R Makar; Jonathan D Smout; Francesco Torella
Journal:  Cochrane Database Syst Rev       Date:  2017-04-03

2.  Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.

Authors:  Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

3.  Hybrid endarterectomy and endovascular therapy in multilevel lower extremity arterial disease involving the femoral artery bifurcation.

Authors:  Junjie Zou; Yongxiang Xia; Hongyu Yang; Hao Ma; Xiwei Zhang
Journal:  Int Surg       Date:  2012 Jan-Mar

4.  Assisting Vascular Surgery with Smartphone Augmented Reality.

Authors:  Omar Aly
Journal:  Cureus       Date:  2020-05-08

5.  Application of relay puncture technique in treating patients with complicated lower extremity arterial diseases.

Authors:  Chengzhi Li; Huimin You; Hong Zhang; Yulong Liu; Wanghai Li; Xiaobai Wang; Yan Zhang
Journal:  PeerJ       Date:  2019-02-13       Impact factor: 2.984

6.  Long-term results after femoral thrombendarterectomy combined with simultaneous endovascular intervention in intermittent claudication and critical ischemia.

Authors:  Martin Altreuther; Erney Mattsson
Journal:  SAGE Open Med       Date:  2020-01-15

7.  Comparison of hybrid procedure and open surgical revascularization for multilevel infrainguinal arterial occlusive disease.

Authors:  Min Zhou; Dian Huang; Chen Liu; Zhao Liu; Min Zhang; Tong Qiao; Chang-Jian Liu
Journal:  Clin Interv Aging       Date:  2014-09-22       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.